JOP20240010A1 - بروتينات actrii واستخداماتها - Google Patents

بروتينات actrii واستخداماتها

Info

Publication number
JOP20240010A1
JOP20240010A1 JOJO/P/2024/0010A JOP20240010A JOP20240010A1 JO P20240010 A1 JOP20240010 A1 JO P20240010A1 JO P20240010 A JOP20240010 A JO P20240010A JO P20240010 A1 JOP20240010 A1 JO P20240010A1
Authority
JO
Jordan
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient receiving
Prior art date
Application number
JOJO/P/2024/0010A
Other languages
Arabic (ar)
English (en)
Inventor
De Oliveira Pena Janethe
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of JOP20240010A1 publication Critical patent/JOP20240010A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JOJO/P/2024/0010A 2021-07-19 2024-01-18 بروتينات actrii واستخداماتها JOP20240010A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (1)

Publication Number Publication Date
JOP20240010A1 true JOP20240010A1 (ar) 2024-01-18

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0010A JOP20240010A1 (ar) 2021-07-19 2024-01-18 بروتينات actrii واستخداماتها

Country Status (18)

Country Link
US (1) US20240327494A1 (https=)
EP (1) EP4373577A4 (https=)
JP (1) JP2024526820A (https=)
KR (1) KR20240049857A (https=)
CN (1) CN117957014A (https=)
AU (1) AU2022316103A1 (https=)
CA (1) CA3225613A1 (https=)
CL (1) CL2024000151A1 (https=)
CO (1) CO2024001551A2 (https=)
CR (1) CR20240061A (https=)
DO (1) DOP2024000016A (https=)
EC (1) ECSP24012819A (https=)
GE (1) GEAP202416461A (https=)
IL (1) IL310141A (https=)
JO (1) JOP20240010A1 (https=)
MX (1) MX2024000829A (https=)
PE (1) PE20240777A1 (https=)
WO (1) WO2023003815A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055822A1 (en) * 2015-03-13 2018-03-01 Repoceuticals Aps Melatonin for Preventing and Treating Radiation Cystitis
CA3005975A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HRP20210694T1 (hr) * 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije

Also Published As

Publication number Publication date
CR20240061A (es) 2024-05-02
EP4373577A4 (en) 2025-05-14
CL2024000151A1 (es) 2024-08-09
JP2024526820A (ja) 2024-07-19
CA3225613A1 (en) 2023-01-26
WO2023003815A9 (en) 2023-05-11
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
IL310141A (en) 2024-03-01
WO2023003815A1 (en) 2023-01-26
AU2022316103A1 (en) 2024-02-08
EP4373577A1 (en) 2024-05-29
ECSP24012819A (es) 2024-03-01
US20240327494A1 (en) 2024-10-03
GEAP202416461A (en) 2024-04-25
MX2024000829A (es) 2024-04-12
CO2024001551A2 (es) 2024-03-07
CN117957014A (zh) 2024-04-30
DOP2024000016A (es) 2024-06-16

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
JOP20240010A1 (ar) بروتينات actrii واستخداماتها
JOP20190097A1 (ar) الجلوبولينات المناعية واستخداماتها
MY205933A (en) Sirp-alpha binding proteins and methods of use thereof
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
MY208638A (en) Anti-steap1 antigen-binding protein
MX381232B (es) Formulación de anticuerpos.
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
SA523451800B1 (ar) Sirp أجسام مضادة لـ ألفا
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
PH12022553106A1 (en) Sars-cov-2-antibodies and methods of selecting and using the same
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MX2019014504A (es) Inmunoglobulinas de union a agrecano.
MX2019012579A (es) Métodos y composiciones para tratar el cáncer con péptidos de afinidad de mec ligados a anticuerpos inmunoterapéuticos.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
MX2023005896A (es) Variantes de anticuerpos bovinos.
EA201992513A1 (ru) Способ лечения рака груди
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
CL2020002459A1 (es) Variantes de anticuerpo c-terminales